Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation

被引：0
|
作者：
Rugo, H. S. [1 ]
Quek, R. [2 ]
Ettl, J. [3 ]
Hurvitz, S. A. [4 ]
Bhattacharyya, H. [2 ]
Hannah, A. L. [5 ]
Litton, J. K. [6 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA
[2] Pfizer Inc, Hlth Econ, San Francisco, CA USA
[3] Tech Univ Munich, Obs Gyn, Munich, Germany
[4] Univ Calif Los Angeles, Hematol Oncol, Santa Monica, CA USA
[5] Pfizer Inc, Oncol, San Francisco, CA USA
[6] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
292O
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA1/2 MUTATION (GBRCAM) RECEIVING TALAZOPARIB (TALA) VS PHYSICIAN'S CHOICE CHEMOTHERAPY TREATMENT (PCT): A FOCUS ON THE EMBRACA HR+/HER2-SUBPOPULATION
    Hurvitz, Sara A.
    Quek, Ruben G. W.
    Ettl, Johannes
    Rugo, Hope
    Bhattacharyya, Helen
    Hannah, Alison L.
    Litton, Jennifer Keating
    BREAST, 2018, 41 : S27 - S28
  • [2] Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician's choice chemotherapy (PCT) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trial
    Rugo, H. S.
    Niyazov, A.
    Bhattacharyya, H.
    Arondekar, B.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S480 - S480
  • [3] Patient Reported Outcomes (PRO) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/without visceral disease
    Ettl, J.
    Quek, R. G. W.
    Bhattacharyya, H.
    Rugo, H. S.
    Hurvitz, S. A.
    Goncalves, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 129 - +
  • [4] PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS (PTS) WITH HER2-ADVANCED BREAST CANCER (ABC) RECEIVING TALAZOPARIB (TALA) VS PHYSICIAN'S CHOICE CHEMOTHERAPY (PCT): A FOCUS ON EMBRACA GERMLINE BRCA1 AND BRCA2 MUTATION (GBRCA1/2M) SUBGROUPS
    Goncalves, Anthony
    Quek, Ruben G. W.
    Bhattacharyya, Helen
    Ettl, Johannes
    Hurvitz, Sara A.
    Rugo, Hope S.
    BREAST, 2019, 48 : S71 - S71
  • [5] PATIENT REPORTED OUTCOMES (PRO) OF TALAZOPARIB (TALA) VERSUS PHYSICIAN'S CHOICE OF CHEMOTHERAPY (PCT) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA (GBRCA) MUTATION: A FOCUS ON EMBRACA PTS WITH/WITHOUT PRIOR CHEMOTHERAPY (CT) SUBGROUPS
    Quek, R. G. W.
    Bhattacharyya, H.
    Goncalves, A.
    Rugo, H. S.
    Hurvitz, S. A.
    Ettl, J.
    VALUE IN HEALTH, 2019, 22 : S532 - S532
  • [6] EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment
    Martin, M.
    Eiermann, W.
    Rugo, H. S.
    Ettl, J.
    Hurvitz, S. A.
    Goncalves, A.
    Yerushalmi, R.
    Markova, D.
    Tudor, I. C.
    Blum, J. L.
    Hannah, A. L.
    Litton, J. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 96 - 96
  • [7] Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib vs physician's choice of chemotherapy: A focus on EMBRACA ECOG performance status subgroups
    Rugo, Hope S.
    Quek, Ruben G. W.
    Bhattacharyya, Helen
    Goncalves, Anthony
    Ettl, Johannes
    Hurvitz, Sara A.
    CANCER RESEARCH, 2020, 80 (04)
  • [8] EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis
    Goncalves, A.
    Eiermann, W.
    Rugo, H. S.
    Ettl, J.
    Hurvitz, S. A.
    Yerushalmi, R.
    Martin, M.
    Al-Adhami, M.
    Tudor, I. C.
    Blum, J. L.
    Hannah, A. L.
    Litton, J. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial
    Ettl, Johannes
    Hurvitz, Sara A.
    Rugo, Hope S.
    Lee, Kyung-Hun
    Mina, Lida A.
    Woodward, Natasha E.
    Yerushalmi, Rinat
    Diab, Sami
    Martin, Miguel
    Tudor, Iulia Cristina
    Czibere, Akos Gabor
    Gauthier, Eric Roland
    Litton, Jennifer Keating
    Goncalves, Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial
    Ettl, J.
    Quek, R. G. W.
    Lee, K. -H.
    Rugo, H. S.
    Hurvitz, S.
    Goncalves, A.
    Fehrenbacher, L.
    Yerushalmi, R.
    Mina, L. A.
    Martin, M.
    Roche, H.
    Im, Y. -H.
    Markova, D.
    Bhattacharyya, H.
    Hannah, A. L.
    Eiermann, W.
    Blum, J. L.
    Litton, J. K.
    ANNALS OF ONCOLOGY, 2018, 29 (09) : 1939 - 1947
12345